MX2019003698A - Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. - Google Patents
Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada.Info
- Publication number
- MX2019003698A MX2019003698A MX2019003698A MX2019003698A MX2019003698A MX 2019003698 A MX2019003698 A MX 2019003698A MX 2019003698 A MX2019003698 A MX 2019003698A MX 2019003698 A MX2019003698 A MX 2019003698A MX 2019003698 A MX2019003698 A MX 2019003698A
- Authority
- MX
- Mexico
- Prior art keywords
- elafibranor
- pharmaceutically acceptable
- acceptable salt
- composition
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición que comprenda como principio activo una sal farmacéuticamente aceptable de elafibranor caracterizada porque la sal farmacéuticamente aceptable de elafibranor se selecciona entre al menos una sal de colina, o de etanolamina, o de dietanolamina, o de L-lisina, o de piperazina, o de calcio, o de trometamina. La invención se refiere más especialmente al uso de sales de elafibranor destinadas a mejorar la estabilidad y la solubilidad en comparación con elafibranor en su forma de base. Estas sales permiten establecer formulaciones farmacéuticas en diferentes formas ventajosas como las inyecciones intravenosas o las formulaciones por vía enteral que muestran una absorción más rápida, menos variable y, en consecuencia, una biodisponibilidad mejor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1659438A FR3056909B1 (fr) | 2016-09-30 | 2016-09-30 | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
| PCT/EP2017/074701 WO2018060372A1 (fr) | 2016-09-30 | 2017-09-28 | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003698A true MX2019003698A (es) | 2020-08-13 |
Family
ID=58347454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003698A MX2019003698A (es) | 2016-09-30 | 2017-09-28 | Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11185520B2 (es) |
| EP (1) | EP3518916B1 (es) |
| CN (1) | CN110234320B (es) |
| BR (1) | BR112019006435A2 (es) |
| CA (1) | CA3038726A1 (es) |
| FR (1) | FR3056909B1 (es) |
| MX (1) | MX2019003698A (es) |
| WO (1) | WO2018060372A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220133666A1 (en) | 2016-03-31 | 2022-05-05 | Genfit | Methods of treatment of cholestatic diseases |
| US20200283381A1 (en) * | 2017-11-16 | 2020-09-10 | Teva Pharmaceuticals International Gmbh | Solid state forms of elafibranor |
| EP3830070A1 (en) * | 2018-08-03 | 2021-06-09 | Genfit | Elafibranor salts |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115605192A (zh) * | 2020-05-18 | 2023-01-13 | 基恩菲特公司（Fr） | 用于治疗原发性硬化性胆管炎的伊拉非布拉诺尔 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841900B1 (fr) * | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
| CN101780049A (zh) * | 2009-01-20 | 2010-07-21 | 北京利乐生制药科技有限公司 | 一种以菲诺贝特酸及其盐为主要成份的肠溶固体制剂及其制备方法 |
| CN101863780A (zh) * | 2009-04-15 | 2010-10-20 | 北京利乐生制药科技有限公司 | 一种降血脂药物胆碱盐及其制备方法、医药用途 |
| MX2012006062A (es) * | 2009-11-26 | 2012-06-28 | Genfit | Uso de derivados de 1,3-difenilprop-2-en-1-ona para el tratamiento de trastornos hepaticos. |
| US9221751B2 (en) | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| AU2012212269B2 (en) * | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| WO2016154258A1 (en) * | 2015-03-26 | 2016-09-29 | T3D Therapeutics, Inc. | Methods of treating liver disease using indane acetic acid derivatives |
-
2016
- 2016-09-30 FR FR1659438A patent/FR3056909B1/fr active Active
-
2017
- 2017-09-28 CA CA3038726A patent/CA3038726A1/fr not_active Abandoned
- 2017-09-28 WO PCT/EP2017/074701 patent/WO2018060372A1/fr unknown
- 2017-09-28 EP EP17777046.8A patent/EP3518916B1/fr active Active
- 2017-09-28 MX MX2019003698A patent/MX2019003698A/es unknown
- 2017-09-28 BR BR112019006435A patent/BR112019006435A2/pt not_active Application Discontinuation
- 2017-09-28 US US16/338,219 patent/US11185520B2/en active Active
- 2017-09-28 CN CN201780073672.7A patent/CN110234320B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| FR3056909B1 (fr) | 2019-04-19 |
| US11185520B2 (en) | 2021-11-30 |
| EP3518916B1 (fr) | 2021-07-07 |
| CA3038726A1 (fr) | 2018-04-05 |
| US20190274982A1 (en) | 2019-09-12 |
| CN110234320A (zh) | 2019-09-13 |
| FR3056909A1 (fr) | 2018-04-06 |
| EP3518916A1 (fr) | 2019-08-07 |
| BR112019006435A2 (pt) | 2019-06-25 |
| CN110234320B (zh) | 2023-10-24 |
| WO2018060372A1 (fr) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003698A (es) | Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| NZ631100A (en) | Soft chewable pharmaceutical products | |
| MX2018004328A (es) | Composiciones farmaceuticas estabilizantes de camptotecina. | |
| EA201290976A1 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| MX2018002462A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
| EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| BR112016024020A8 (pt) | composição farmacêutica | |
| PH12016501519A1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| MX2016008729A (es) | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. | |
| BR112018017005A2 (pt) | composto derivado de entecavir e composição farmacêutica para prevenir ou tratar hepatite b | |
| EA201400484A1 (ru) | Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| MY191983A (en) | Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same | |
| EA201700072A1 (ru) | Способ получения стабилизированной фармацевтической композиции в виде водного раствора | |
| PL419082A1 (pl) | Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol | |
| CA3010857A1 (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate |